In terms of BC treatment response, HIF1α expression is associated with endocrine therapy resistance in BC (Jogi et al., 2019; Morotti et al., 2019) and also lapatinib resistance in HER2-positive BC (Karakashev and Reginato, 2015). Here, HIF1A is linked to breast cancer.